Abstract:Studies from recent years have identified a diverse population of both bacteria and fungi in the human vagina and several community signatures have emerged that are associated with susceptibility to infectious disease. A healthy vaginal bacterial microbiome is most frequently dominated by Lactobacillus species [1], yet a combination of other genera are isolated in vaginal swabs in both healthy and diseased states. The vaginal fungal mycobiome is dominated by Ascomycota, of which Candida species are the most abundant. Approximately 20% to 30% of healthy human vaginal samples contain detectable Candida at a single time point, with nearly all of those being C . albicans , and 70% of the population is expected to be vaginally colonized with Candida longitudinally [2]. Despite its prevalence in the healthy vaginal mycobiome, C . albicans is the most common causative agent of vulvovaginal candidiasis (VVC), a cause of significant morbidity in the human population. The next most common species implicated in VVC is C . glabrata , while other species including C . lusitaniae , C . tropicalis , C . parapsilosis , and C . krusei are also known to contribute to vaginal infections [3–5]. Non- albicans Candida species are typically more resistant to antifungal drugs than C . albicans [6], complicating therapeutic options and increasing treatment timelines. A disease state is often distinguished by an exaggerated inflammatory response at the vaginal mucosa [3] that leads to vulvar pruritis and erythema [7]. Polymorphic Candida species can initiate the process of filamentation, morphogenesis from single-celled yeast to multicellular hyphae, which is typically accompanied by increased tissue damage and inflammation [8]. Microbial dysbiosis has long been associated with VVC due to the observation that antibiotic usage dramatically increases the risk of onset. This notion has been challenged by several population studies [9,10]; however, other studies have found a close association between Candida and specific bacteria as well as distinct Lactobacillus species that were associated with decreased observation of fungi in samples or symptomatic VVC [11–15]. Taken together, the evidence suggests that specific bacterial species can have complex impacts on fungal burden and symptomatic infection. Shifts in the vaginal microbiome are also associated with other genital tract infections [13,16] including bacterial vaginosis (BV) and aerobic vaginitis (AV), which are characterized by the displacement of Lactobacillus species by other bacteria such as Gardnerella vaginalis , Streptococcus agalactiae , Staphylococcus aureus , Escherichia coli , and Enterococcus faecalis [17]. Both BV and AV are polymicrobial in nature and are associated with concurrent Candida carriage in many cases [18,19]. Mixed vaginitis, which can include BV or AV together with VVC, is particularly difficult to treat, and during late stages of pregnancy can lead to severe adverse maternal and neonatal outcomes [17,20]. Because it is the most abundant fungal genus in the vagina, this review will focus on the interactions between Candida species and the healthy and pathogenic bacteria found in the vaginal environment. These interactions play a significant role in maintaining homeostasis as well as impacting disease pathogenesis in the genital tract (Fig 1).

The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections

Vaginal Microbiota: Potential Targets for Vulvovaginal Candidiasis Infection.

Impact of interkingdom microbial interactions in the vaginal tract

Probiotics in the Management of Vulvovaginal Candidosis

A molecular view on the interference established between vaginal lactobacilli and pathogenic Candida species : challenges and opportunities for the development of new therapies

Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review

Candida causes recurrent vulvovaginal candidiasis by forming morphologically disparate biofilms on the human vaginal epithelium

Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review

Biofilm in Bacterial Vaginosis: A Legitimate Therapeutic Challenge?

Synergistic Inhibition of Synbiotic Cultures among Lactobacilli and Plant Extracts against Vaginal Discharge Causing Candida albicans

RAFT-Derived Polymethacrylates as a Superior Treatment for Recurrent Vulvovaginal Candidiasis by Targeting Biotic Biofilms and Persister Cells

The Interplay between Candida albicans, Vaginal Mucosa, Host Immunity and Resident Microbiota in Health and Disease: An Overview and Future Perspectives

Probiotic Interference of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 with the Opportunistic Fungal Pathogen Candida albicans

Insights into Women's health: Exploring the vaginal microbiome, quorum sensing dynamics, and therapeutic potential of quorum sensing quenchers

The microbial revolution: Unveiling the benefits of vaginal probiotics and prebiotics

Bacterial Vaginosis and Vulvovaginal Candidiasis Pathophysiologic Interrelationship

Antifungal susceptibility and biofilm production of Candida species- causative agents of female genital tract infections

Intestinal Infection of Candida albicans: Preventing the Formation of Biofilm by C. albicans and Protecting the Intestinal Epithelial Barrier

In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China

A narrative review on bacterial biofilm: its formation, clinical aspects and inhibition strategies

Inhibitory effects of vaginal Lactobacilli on C andida albicans growth, hyphal formation, biofilm development, and epithelial cell adhesion